The role of surgery in oligometastatic esophageal squamous cell carcinoma (ESCC) remains controversial. This study evaluated the oncological outcomes after esophagectomy in patients with ESCC with distant lymph node (LN) metastasis. Patients with ESCC and nodal metastasis treated with chemoradiotherapy or chemotherapy followed by esophagectomy between 2010 and 2020 were included. Overall survival (OS) and recurrence-free survival (RFS) were compared between patients with distant LN metastasis (dLN+) and exclusively regional LN metastasis (dLN-). The cohort comprised 69 dLN+ and 111 dLN- patients. Survival was significantly better in the dLN- group than in the dLN+ group (5-year OS, 51.9% vs. 25.5%, P < 0.001; RFS, 47.2% vs. 18.1%, P < 0.001). Stratified by the yp stage, 49 (44.1%) dLN- and 30 (43.5%) dLN+ patients achieved a pathological complete response (pCR). In the dLN- and dLN+ groups, the OS rates were significantly higher in the pCR group than in the non-pCR group (dLN-: 76.7% vs. 32.4%, P < 0.001; dLN+: 39.6% vs. 14.2%; P = 0.002). The dLN-/pCR group had the best OS, significantly outperforming the dLN-/non-pCR and dLN+/pCR groups. OS did not differ between the dLN-/non-pCR and dLN+/pCR groups. The dLN+/non-pCR group had the worst OS. The RFS analysis paralleled the OS findings. Patients with dLN+ disease had worse outcomes than their dLN- counterparts, irrespective of the pCR status. The survival rates were poor but comparable between the dLN+/pCR and dLN-/non-pCR groups. Adjuvant therapy may be required for dLN+ patients following systemic treatment and surgery, even after achieving pCR.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1093/dote/doae064 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Esophagectomy Trends and Postoperative Outcomes at Private Equity-Acquired Health Centers.
JAMA Surg
January 2025
Department of Surgery, University of Michigan, Ann Arbor.
Article Synopsis
- This study investigates the impact of private equity acquisition on the quality of care for patients undergoing esophagectomy in US hospitals.
- It compares patient outcomes, specifically focusing on 30-day postoperative complications and mortality, between private equity-acquired hospitals and nonacquired facilities.
- Findings reveal that patients at private equity-acquired hospitals have higher mortality rates and lower annual surgical procedure volumes compared to those at nonacquired hospitals.
Analysis of the short-term efficacy of 2 versus 3 cycles of neoadjuvant immunotherapy combined with chemotherapy in patients with esophageal squamous cell carcinoma.
J Cancer
January 2025
Department of Thoracic Surgery, the First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
Article Synopsis
- Neoadjuvant immunotherapy plus chemotherapy shows significant effects on locally advanced esophageal squamous cell carcinoma (LA-ESCC), but the ideal number of treatment cycles remains debated.
- A study involving 100 patients compared the outcomes between those receiving 2 vs. 3 cycles of treatment, focusing on pathologic complete response rates, surgical results, and complications.
- Results showed similar effectiveness and safety between the two cycles, with no notable differences in complications; however, the inflammation marker NLR decreased significantly in some patients after the third cycle, suggesting potential benefits for certain individuals.
Adjuvant immunotherapy after neoadjuvant immunochemotherapy and esophagectomy for esophageal squamous cell carcinoma: a real-world study.
Front Immunol
January 2025
Department of Thoracic Oncological Surgery, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, China.
Background: The role of immunotherapy in the adjuvant setting seems promising in recent years. As per the findings of the CheckMate 577 trial, patients with esophageal cancer (EC) who had neoadjuvant chemoradiation with residual pathologic disease should be considered adjuvant immunotherapy (AIT). However, it is unknown if individuals with esophageal squamous cell carcinoma (ESCC) who have received neoadjuvant immunochemotherapy (NICT) followed by radical surgery also require AIT.
View Article and Find Full Text PDFTwenty years of anastomotic stenosis combined with tracheocolonic fistula after colon replacement esophagectomy: a case report.
Front Oncol
December 2024
Lanshan District People's Hospital, Department of Thoracic Surgery, Linyi, Shandong, China.
Esophageal stricture is the most common and disabling complication of esophageal injury caused by ingestion of corrosive substances. In our case, the patient developed esophageal stenosis due to ingestion of strong alkaline substances and underwent colon replacement surgery after repeated failed dilation treatments. After surgery, anastomotic stenosis and tracheocolonic fistula occurred successively, and the entire diagnosis and treatment cycle of this disease lasted for more than 20 years.
View Article and Find Full Text PDFRobotic-Assisted Minimally Invasive Resection of Multiple Oesophageal Schwannomas: A Case Report.
Cureus
November 2024
Department of Upper Gastrointestinal and Hepatobiliary Surgery, Monash Health, Melbourne, AUS.
Schwannomas are rare, benign tumours arising from Schwann cells, with oesophageal cases representing a small fraction. Their variety of symptoms and nonspecific imaging features often make preoperative diagnosis challenging, frequently requiring immunohistochemical staining for confirmation. We describe the case of a 62-year-old woman with progressive dysphagia, found to have a subepithelial mass at the gastroesophageal junction (GOJ).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!